Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B London

Showing results (141-150 of 310) with videos related to

Pageof 31
Sort By:
Pediatric Blood & Cancer|September 17, 2013
Neuroblastoma in older children, adolescents and young adults: a report from the International Neuroblastoma Risk Group projectYaël P Mossé, Rebecca J Deyell, Frank Berthold, et al.
Blood|July 9, 2009
A risk-adapted, response-based approach using ABVE-PC for children and adolescents with intermediate- and high-risk Hodgkin lymphoma: the results of P9425Cindy L Schwartz, Louis S Constine, Doojduen Villaluna, et al.
AJNR. American Journal of Neuroradiology|June 15, 2023
Correlation between Multiparametric MR Imaging and Molecular Genetics in Pontine Pediatric High-Grade GliomaV Rameh, S Vajapeyam, A Ziaei, et al.
Journal of the National Cancer Institute|December 18, 2012
Trans-population analysis of genetic mechanisms of ethnic disparities in neuroblastoma survivalEric R Gamazon, Navin Pinto, Anuar Konkashbaev, et al.
Pediatric Blood & Cancer|March 27, 2015
SIOP-PODC adapted risk stratification and treatment guidelines: Recommendations for neuroblastoma in low- and middle-income settingsNehal S Parikh, Scott C Howard, Guillermo Chantada, et al.
Pediatric Blood & Cancer|September 16, 2023
Phase 1 study of cabozantinib in combination with topotecan-cyclophosphamide for patients with relapsed Ewing sarcoma or osteosarcomaKevin Campbell, Andrew Posner, Nan Chen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 25, 2023
Survival of Patients With Neuroblastoma After Assignment to Reduced Therapy Because of the 12- to 18-Month Change in Age Cutoff in Children's Oncology Group Risk StratificationHannah G Bender, Meredith S Irwin, Michael D Hogarty, et al.
Cell Death and Differentiation|January 22, 2011
CASZ1, a candidate tumor-suppressor gene, suppresses neuroblastoma tumor growth through reprogramming gene expressionZ Liu, X Yang, Z Li, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 15, 2014
Ototoxicity in children with high-risk neuroblastoma: prevalence, risk factors, and concordance of grading scales--a report from the Children's Oncology GroupWendy Landier, Kristin Knight, F Lennie Wong, et al.
European Journal of Cancer (Oxford, England : 1990)|April 5, 2019
Predictors of differential response to induction therapy in high-risk neuroblastoma: A report from the Children's Oncology Group (COG)Navin Pinto, Arlene Naranjo, Emily Hibbitts, et al.
Pageof 31

Showing results (141-150 of 310) with videos related to

Sort By:
Pageof 31
Pediatric Blood & Cancer|September 17, 2013
Neuroblastoma in older children, adolescents and young adults: a report from the International Neuroblastoma Risk Group projectYaël P Mossé, Rebecca J Deyell, Frank Berthold, et al.
Blood|July 9, 2009
A risk-adapted, response-based approach using ABVE-PC for children and adolescents with intermediate- and high-risk Hodgkin lymphoma: the results of P9425Cindy L Schwartz, Louis S Constine, Doojduen Villaluna, et al.
AJNR. American Journal of Neuroradiology|June 15, 2023
Correlation between Multiparametric MR Imaging and Molecular Genetics in Pontine Pediatric High-Grade GliomaV Rameh, S Vajapeyam, A Ziaei, et al.
Journal of the National Cancer Institute|December 18, 2012
Trans-population analysis of genetic mechanisms of ethnic disparities in neuroblastoma survivalEric R Gamazon, Navin Pinto, Anuar Konkashbaev, et al.
Pediatric Blood & Cancer|March 27, 2015
SIOP-PODC adapted risk stratification and treatment guidelines: Recommendations for neuroblastoma in low- and middle-income settingsNehal S Parikh, Scott C Howard, Guillermo Chantada, et al.
Pediatric Blood & Cancer|September 16, 2023
Phase 1 study of cabozantinib in combination with topotecan-cyclophosphamide for patients with relapsed Ewing sarcoma or osteosarcomaKevin Campbell, Andrew Posner, Nan Chen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 25, 2023
Survival of Patients With Neuroblastoma After Assignment to Reduced Therapy Because of the 12- to 18-Month Change in Age Cutoff in Children's Oncology Group Risk StratificationHannah G Bender, Meredith S Irwin, Michael D Hogarty, et al.
Cell Death and Differentiation|January 22, 2011
CASZ1, a candidate tumor-suppressor gene, suppresses neuroblastoma tumor growth through reprogramming gene expressionZ Liu, X Yang, Z Li, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 15, 2014
Ototoxicity in children with high-risk neuroblastoma: prevalence, risk factors, and concordance of grading scales--a report from the Children's Oncology GroupWendy Landier, Kristin Knight, F Lennie Wong, et al.
European Journal of Cancer (Oxford, England : 1990)|April 5, 2019
Predictors of differential response to induction therapy in high-risk neuroblastoma: A report from the Children's Oncology Group (COG)Navin Pinto, Arlene Naranjo, Emily Hibbitts, et al.
Pageof 31